Articles tagged with: Decadron
Press Releases»

Oxford, United Kingdom (Press Release) – In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
On 8 June, recruitment to the dexamethasone arm was halted since, in the view of the trial Steering Committee, sufficient patients had been enrolled to establish whether or not the drug had …
Opinion»

As you may remember from my previous column, I started treatment with Darzalex, Revlimid, and dexamethasone in early October.
By now, I have received six weekly Darzalex (daratumumab) infusions, and quite a bit has happened as I adjust to being on a new regimen.
After the first infusion, I had a mild cough that turned into quite a deep, hacking cough. I could hardly sleep for a week. It didn’t appear to be a "productive" cough, so I took Benadryl (diphenhydramine) and cough medicines and sat upright a lot at …
Opinion»

The world may not be ready for the 500th column on the joys of dexamethasone (Decadron), but today is a dex day for me, so here it goes anyway.
I have a fair bit of experience with the corticosteroid dex, starting with my myeloma diagnosis back in 2006. My initial treatment consisted of thalidomide (Thalomid) and dex, and I was on the two drugs for about eight months. This combination did well, getting me into complete remission before my autologous stem cell transplant. I had the then-current dosage of 40 …
News, Opinion»

A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it is again …
News»

Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial comparing Kyprolis-Revlimid-dexamethasone to Revlimid-dexamethasone in patients with relapsed multiple myeloma.
Patients in the trial who received the Kyprolis-Revlimid-dexamethasone combination (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dexamethasone (Rd) (17.6 months).
There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. However, the difference is not yet statistically significant.
The results of the trial are important for two reasons.
First, …
News»

French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexamethasone (RVD) in newly diagnosed multiple myeloma patients.
The researchers found that RVD, when given before and after stem cell transplantation – and when followed by maintenance therapy with Revlimid – led to very deep treatment responses and significant survival rates.
The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy. Next, the trial participants underwent autologous (own) stem cell transplants, followed …
News»

Findings from a prospective Phase 2 clinical trial indicate that the combination of Revlimid, Velcade, and dexamethasone is effective in relapsed and refractory multiple myeloma patients.
The trial enrolled 64 patients, who had been treated with a median of two prior therapies, at six different U.S. cancer centers from 2006 to 2008.
Nearly two-thirds of the patients in the trial achieved at least a partial response, despite the fact that more than half of the patients had previously been treated with Velcade (bortezomib), and nearly three quarters had previously been …